Skip to main content

Table 1 Patient characteristics

From: High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease

Patients (n, %) 714 100
   Male (n, %) 345 48.3
   Female (n, %) 369 51.7
Age, years (median, IQR) 35 30 - 42
   Clinical stage   
   CDC A (n, %) 354 49.6
   CDC B (n, %) 158 22.1
   CDC C (n, %) 202 28.3
CD4+ T cell count, cells/μL (median, IQR) 350 220 - 533
CD4+ T cells, percent (median, IQR) 21.0 15.0 - 29.0
CD8+ T cell count, cells/μL (median, IQR) 808 565 - 1133
CD8+ T cells, percent (median, IQR) 51.0 41.0 - 59.0
Patients with HIV-1 RNA <50 copies/mL (n, %) 308 43.1
Patients with HIV-1 RNA ≥50 copies/mL (n, %) 406 56.9
HIV-1 RNA among these (log [copies/mL], IQR) 3.94 2.97-4.68
HIV-1 clade (n, %)   
   B 94 13.2
   Non-B (15 different clades) 620 86.8
Treatment status   
   HAART-naive (n, %) 190 26.6
   Receiving HAART (n, %) 524 73.4
   Months on HAART if receiving HAART (median, IQR) 13.5 11.1 - 17.8